[1]冯思源,郑薇,张瑞国,等.甲状腺微小乳头状癌与乳头状非微小癌的临床特点及131I疗效的比较研究[J].国际放射医学核医学杂志,2018,(2):111-114,153.[doi:10.3760/cma.j.issn.1673-4114.2018.02.003]
　Feng Siyuan,Zheng Wei,Zhang Ruiguo,et al.Clinical characteristics and 131I efficacy of papillary thyroid microcarcinoma and papillary thyroid non-micro carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):111-114,153.[doi:10.3760/cma.j.issn.1673-4114.2018.02.003]
点击复制

甲状腺微小乳头状癌与乳头状非微小癌的临床特点及131I疗效的比较研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第2期
页码:
111-114,153
栏目:
临床研究
出版日期:
2018-05-09

文章信息/Info

Title:
Clinical characteristics and 131I efficacy of papillary thyroid microcarcinoma and papillary thyroid non-micro carcinoma
作者:
冯思源;  郑薇;  张瑞国;  王任飞;  张桂芝;  谭建
300052, 天津医科大学总医院核医学科
Author(s):
Feng Siyuan;  Zheng Wei;  Zhang Ruiguo;  Wang Renfei;  Zhang Guizhi;  Tan Jian
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
甲状腺肿瘤; 碘放射性同位素; 甲状腺微小乳头状癌; 甲状腺乳头状癌; 临床特点; 预后
Keywords:
Thyroid neoplasms; Iodine radioisotopes; Papillary thyroid microcarcinoma; Papillary thyroid carcinoma; Clinical feature; Prognosis
DOI:
10.3760/cma.j.issn.1673-4114.2018.02.003
摘要:
目的 研究比较甲状腺微小乳头状癌（PTMC）和除PTMC以外的甲状腺乳头状癌（PTC）的临床特点及131I疗效。方法 将369例行甲状腺全切术后拟行131I治疗的PTC患者，按照肿瘤直径分为PTMC组（≤ 1.0 cm）和PTC组（>1.0 cm）。回顾性分析两组患者的临床资料并评估患者的预后，应用SPSS22.0统计软件对结果进行t检验和卡方检验统计分析。结果 PTMC组发生淋巴结转移和中央区淋巴结转移的患者比例均低于PTC组，且转移的淋巴结数量更少，差异有统计学意义（χ2=44.23、23.56、42.80，均P<0.05）。与PTC组相比，PTMC组患者大多单叶发病（χ2=45.94，P<0.05）且更少发生包膜侵犯（χ2=11.22，P<0.05），PTMC组有更多的患者合并桥本氏甲状腺炎，两者间的差异有统计学意义（χ2=9.08，P<0.05）。2组患者发生远处转移及合并毒性弥漫性甲状腺肿和结节性甲状腺肿等良性疾病的情况之间的差异无统计学意义（χ2=8.09、2.16、0.21，均P>0.05）。2组共197例患者经过治疗达到临床缓解，其中PTMC组患者治疗后的缓解率（67.53%）高于PTC组（37.71%）。197例达到临床缓解的患者中有102例经首次治疗即达到临床缓解。虽然PTMC组经首次治疗即达到临床缓解的患者多于PTC组，但两组间差异无统计学意义（χ2=3.18，P>0.05）。结论 PTMC患者的临床特点不同于乳头状非微小癌患者，经131I治疗后PTMC总体治愈率更高。在临床工作中，建议对PTMC患者制定个体化的治疗方案，从而达到更好的治疗效果及预后。
Abstract:
Objective To compare the clinical features and 131I efficacy of papillary thyroid microcarcinoma (PTMC) and papillary thyroid carcinoma (PTC) except for PTMC. Methods PTC patients who were undergoing 131I treatment after total thyroidectomy were divided into the PTMC group (≤ 1.0 cm) and the papillary non-microcarcinoma group (>1.0 cm) according to tumor diameter. The clinical data of both groups were retrospectively analyzed, and the prognoses of the patients were evaluated. The statistical software SPSS Statistics 22.0 was used to analyze the results via t test and chi-squared (χ2) test. Results The proportion of patients with lymph node and central lymph node metastases in the PTMC group was lower than that in the PTC group. The number of metastatic lymph nodes was less, and the difference was statistically significant (χ2=44.23, 23.56, 42.80, all P<0.05). Most of the patients in the PTMC group demonstrated unilateral morbidity (χ2=45.94, P<0.05) and less extranodal infiltrations (χ2=11.22, P<0.05) compared with the patients in the PTC group. The PTMC group included more patients with Hashimoto’s thyroiditis than the PTC group, and the difference between the two groups was statistically significant (χ2=9.08, P<0.05). No significant difference was observed between the two groups with regard to the occurrence of distant metastases and benign diseases, such as diffuse toxic goiter and nodular goiter (χ2=2.16, 0.21, both P>0.05). A total of 197 patients in the two groups achieved clinical remission after treatment. The remission rate in the PTMC group was higher than that in the PTC group. Among the 197 clinical remission cases, 102 patients achieved clinical remission after the first treatment. Although more patients achieved clinical remission in the PTMC group than in the PTC group after the first treatment, no significant difference was noted between the two groups (χ2=3.18, P>0.05). Conclusions The clinical features of PTMC patients differ from those of PTC patients. The overall cure rate of PTMC after 131I treatment is higher than that of PTC. The development of individualized treatment plans for PTMC patients is recommended to achieve good therapeutic effect and prognosis.

参考文献/References:

[1] 严丽,冀宏,李清怀, 等. 甲状腺微小乳头状癌中央区淋巴结转移的临床因素分析[J]. 中华实验外科杂志, 2016, 33(3):765-767. DOI:10.3760/cma.j.issn.1001-9030.2016.03.065. Yan L, Ji H, Li QH, et al. Clinical factors related to central lymph node metastasis in papillary thyroid microcarcinoma[J]. Chin J Exp Surg, 2016, 33(3):765-767.
[2] Qu N, Zhang L, Ji QH, et al. Number of tumor foci predicts prognosis in papillary thyroid cancer[J]. BMC Cancer, 2014, 14:914. DOI:10.1186/1471-2407-14-914.
[3] Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size:a retrospective study of 2309 consecutive patients[J]. Ann Surg Oncol, 2015, 22(1):125-131. DOI:10.1245/s10434-014-3899-8.
[4] Jeon MJ, Kim WG, Kwon H, et al. Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma[J]. Eur J Endocrinol, 2017, 177(1):25-31. DOI:10.1530/EJE-17-0160.
[5] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4):264-278. DOI:10.3760/cma.j.issn.2095-2848.2014.04.002. Nuclear Medical Branch of Chinese Medical Association. Guidelines for 131I in the treatment of differentiated thyroid carcinoma (2014 Edition)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4):264-278.
[6] Pillai S, Gopalan V, Smith RA, et al. Diffuse sclerosing variant of papillary thyroid carcinoma-an update of its clinicopathological features and molecular biology[J]. Crit Rev Oncol Hematol, 2015, 94(1):64-73. DOI:10.1016/j.critrevonc.2014.12.001.
[7] Price AK, Randle RW, Schneider DF, et al. Papillary thyroid microcarcinoma:decision-making, extent of surgery, and outcomes[J]. J Surg Res, 2017, 218:237-245. DOI:10.1016/j.jss.2017. 05. 054.
[8] Creach KM, Siegel BA, Nussenbaum B, et al. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma[J]. ISRN Endocrinol, 2012, 2012:816386. DOI:10.5402/2012/816386.
[9] Park JP, Roh JL, Lee JH, et al. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma[J]. Am J Surg, 2014, 208(3):412-418. DOI:10.1016/j.amjsurg.2013.10.032.
[10] Papini E, Guglielmi R, Gharib H, et al. Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma:a potential therapeutic approach in patients at surgical risk[J]. Thyroid, 2011, 21(8):917-920. DOI:10.1089/thy.2010.0447.
[11] Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf), 2009, 71(4):581-586. DOI:10.1111/j.1365-2265.2009.03537.x.
[12] Jeong JS, Kim HK, Lee CR, et al. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma:clinical manifestation and prognostic outcome[J]. J Korean Med Sci, 2012, 27(8):883-889. DOI:10.3346/jkms.2012.27.8.883.
[13] 葛华, 陈文新. 桥本甲状腺炎合并甲状腺乳头状癌的特征及预后研究进展[J]. 国际放射医学核医学杂志, 2017, 41(6):443-447. DOI:10.3760/cma.j.issn.1673-4114.2017.06.011. Ge H, Chen WX. Research progress of characteristics and prognosis for the Hashimoto’s thyroiditis coexistent with papillary thyroid carcinoma[J]. Inter J Radiat Med Nucl Med, 2017, 41(6):443-447.
[14] Giordano D, Gradoni P, Oretti G, et al. Treatment and prognostic factors of papillary thyroid microcarcinoma[J]. Clin Otolaryngol, 2010, 35(2):118-124. DOI:10.1111/j.1749-4486.2010.02085.x.
[15] 孙丹阳, 郑薇, 张桂芝, 等. 甲状腺全切术后接受131I治疗的微小乳头状癌淋巴结转移临床特点[J]. 中华内分泌代谢杂志, 2016, 32(11):900-905. DOI:10.3760/cma.j.issn.1000-6699.2016.11.003. Sun DY, Zheng W, Zhang GZ, et al. Clinical features of lymph node metastasis in papillary thyroid microcarcinoma with 131I treatment[J]. Chin J Endocrinol Metab, 2016, 32(11):900-905.
[16] 郑薇, 谭建, 张桂芝, 等. 甲状腺全切的微小乳头状癌临床特点的回顾性研究[J]. 中华内分泌代谢杂志, 2015, 31(1):14-17. DOI:10.3760/cma.j.issn.1000-6699.2015.01.004. Zheng W, Tan J, Zhang GZ, et al. A retrospective study of the clinical features in papillary thyroid microcarcinoma[J]. Chin J Endocrinol Metab, 2015, 31(1):14-17.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[13]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[14]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[15]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
　Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[16]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
　Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[17]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
　Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[18]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
　Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[19]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
　HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[20]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
　YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]

备注/Memo

备注/Memo:
收稿日期:2017-12-12。
基金项目:国家自然科学基金青年科学基金（81601523）
通讯作者:谭建,Email:tanpost@163.com
更新日期/Last Update: 2018-05-09